Latest Diagnostic and Treatment Modalities for TTP

α
Ali Ghani
Ali Ghani
σ
AliRaza Ghani
AliRaza Ghani
ρ
Ahsan Raza
Ahsan Raza
ρ Lankenau Institiute of Medical Research

Send Message

To: Author

Latest Diagnostic and Treatment Modalities for TTP

Article Fingerprint

ReserarchID

LADA8

Latest Diagnostic and Treatment Modalities for TTP Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Abstract

TTP is a very uncommon disease which used to have very high mortality and morbidity before the introduction of plasmapharesis and immunosup-pressant therapy. Even after the introduction of these modalities, atypical HUS patients had a very grave prognosis and ultimately led to death in many until the introduction of complement inhibitors like eculizumab which is C5a monoclonal antibody. Additionally differentiating typical HUS versus atypical HUS was very difficult but some work on complement markers can be very fruitful in differentiating them.

References

18 Cites in Article
  1. James George (2010). How I treat patients with thrombotic thrombocytopenic purpura: 2010.
  2. M Scully,B Hunt,S Benjamin (2012). Guidelines on the diagnosis and management of thrombotic thromb-ocytopenic purpura and other thrombotic microan-giopathies.
  3. Giuseppe Remuzzi,Serafino Garella (1987). HUS and TTP: Variable expression of a single entity.
  4. Piero Ruggenenti,Marina Noris,Giuseppe Remuzzi (2001). Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.
  5. S Allford,B Hunt,P Rose (2003). Guidelines on the diagnosis and management of the thrombotic microangiopathichaemolyticanaemias.
  6. H Tsai (2003). Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
  7. Gail Rock,Kenneth Shumak,Noel Buskard,Victor Blanchette,John Kelton,Rama Nair,Robert Spasoff (1991). Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic Purpura.
  8. Sara Vesely,James George,Bernhard Lämmle,Jan-Dirk Studt,Lorenzo Alberio,Mayez El-Harake,Gary Raskob (2003). ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.
  9. J Moake (2002). Thrombotic microangiopathies.
  10. J Sadler (2008). Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
  11. E Amorosi,J Ultmann (1966). Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature.
  12. Von Baeyer,H (2002). Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies.
  13. B Wyllie,A Garg,J Macnab,G Rock,W Clark (2006). Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange.
  14. Mini Michael,Elizabeth Elliott,Greta Ridley,Elisabeth Hodson,Jonathan Craig (2009). Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.
  15. Kremer Hovinga,J Vesely,S Terrell,D (2010). Survival and relapse in patients with thrombotic thromboc-ytopenic purpura.
  16. Samhar Al-Akash,P Almond,Van Savell,Salam Gharaybeh,Cris Hogue (2011). Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.
  17. J Jump Up^ Zuber,Le Quintrec,M Sberro-Soussan,R Loirat,C Frémeaux-Bacchi,V Legendre,C (2011). New insights into postrenal transplant hemolytic uremic syndrome.
  18. Han-Mou Tsai (2010). Pathophysiology of thrombotic thrombocytopenic purpura.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Ali Ghani. 2014. \u201cLatest Diagnostic and Treatment Modalities for TTP\u201d. Global Journal of Medical Research - F: Diseases GJMR-F Volume 14 (GJMR Volume 14 Issue F3): .

Download Citation

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Version of record

v1.2

Issue date

September 13, 2014

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 4593
Total Downloads: 2298
2026 Trends
Related Research

Published Article

TTP is a very uncommon disease which used to have very high mortality and morbidity before the introduction of plasmapharesis and immunosup-pressant therapy. Even after the introduction of these modalities, atypical HUS patients had a very grave prognosis and ultimately led to death in many until the introduction of complement inhibitors like eculizumab which is C5a monoclonal antibody. Additionally differentiating typical HUS versus atypical HUS was very difficult but some work on complement markers can be very fruitful in differentiating them.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Latest Diagnostic and Treatment Modalities for TTP

AliRaza Ghani
AliRaza Ghani
Ahsan Raza
Ahsan Raza Lankenau Institiute of Medical Research

Research Journals